SAN FRANCISCO, June 14, 2011/PRNewswire/ --Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (NASDAQ: MERR), today announced that it will serve as the Principal American Liaison (PAL) for Circadian Technologies Limited (ASX: CIR; OTCQX: CKDXY) as it begins trading on OTCQX®.
Circadian is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses. The Company announced today that it is now trading on the OTC market's highest tier, OTCQX.
OTCQX distinguishes the best companies traded over-the-counter (OTC) from more than 9,000 securities traded on the OTCBB and OTC Link that are not required to meet any financial standards or undergo a qualitative review.
Spencer Grimes, Merriman Capital Managing Director, said: "We are very pleased to see Circadian live on OTCQX today. I have been working with Circadian's CEO, Robert Klupacs, for the past two years and have been continually impressed by the progress his team has made. Circadian's story is one that will continue to attract U.S. institutional and retail investors alike. We are proud to be their partner in this effort."
Robert Klupacs, CEO of Circadian, commented: "Over the past 12 months we have been receiving considerable interest from U.S.-based investors in buying into Circadian, in particular from U.S. retail-orientated broking houses and institutions that have mandates to invest only in U.S.-traded stocks. The establishment of a sponsored ADR Program allows them the opportunity to invest, creates a broader secondary market for the Company's listed securities, and enables U.S. investors to trade in the Company's securities without the hazards of cross-currency transactions."
About Merriman Capital, Inc.
Merriman Capital, Inc. is a full-service investment banking firm that provides investment banking, sales and trading, and equity research services to corporate and institutional clients and high net worth investors. Merriman Capital, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc., which is listed on the NASDAQ Stock Market and trades under the symbol "MERR."
Merriman specializes in four growth sector industries: Technology, Telecom, Consumer, Media & Internet and CleanTech Infrastructure. For more information, please go to http://www.merrimanco.com/.
Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org and the Securities Investor Protection Corporation (SIPC)
About Circadian Technologies Limited
Circadian Technologies Limited (ASX: CIR; OTCQX: CKDXY) is a biologics drug developer focusing on cancer therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF) C and D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are focused on novel anti-cancer therapeutics for large unmet needs. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the antibody-based drug IMC-3C5 targeting VEGFR-3.
The OTCQX marketplace is the premier tier of the U.S. OTC market. Investor-focused companies use the quality-controlled OTCQX platform to offer investors transparent trading, superior information, and easy access through their regulated U.S. broker-dealers. The innovative OTCQX platform offers companies and their shareholders a level of marketplace services formerly available only on a U.S. stock exchange. For more information and to view a full list of OTCQX companies, visit www.otcqx.com.
Note to Investors
This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of the Company. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K/A filed on April 28, 2011.
Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K/A filed on April 28, 2011, together with this press release and the financial information contained herein, are available on our website, www.merrimanco.com. Please click on "Investor Relations."
SOURCE Merriman Holdings, Inc.